Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Topotecan × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 9 Neuroblastoma 8 Ovarian Neoplasms 6 Ganglioneuroblastoma 5 Uterine Cervical Neoplasms 3 Fallopian Tube Neoplasms 3 Neoplasms 2 Brain Neoplasms 2 Wilms Tumor 1 Thrombocythemia, Essential 1 Sarcoma, Ewing 1 Rhabdoid Tumor 1 Recurrence 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Pleuropulmonary blastoma 1 Peritoneal Neoplasms 1 Pediatric Brain Tumor 1 Neoplasm Metastasis 1 Myelodysplastic-Myeloproliferative Diseases 1 Medulloblastoma 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Localized Extraskeletal Ewing Sarcoma 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1 Glioma 1 Fallopian Tube Mucinous Adenocarcinoma 1 Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1

Interventions

Cyclophosphamide 26 fludarabine 21 pembrolizumab 17 Dexamethasone 16 Rituximab 14 venetoclax 12 Gemcitabine 9 Vincristine 8 Temozolomide 8 Lenalidomide 8 Etoposide 8 glofitamab 7 Cytarabine 7 pomalidomide 6 obinutuzumab 6 Prednisone 6 Nivolumab 6 Doxorubicin 6 Calcium Dobesilate 6 zanubrutinib 5 fludarabine phosphate 5 carfilzomib 5 Carboplatin 5 ruxolitinib 4 Radiotherapy 4 Paclitaxel 4 Capecitabine 4 Bortezomib 4 Bevacizumab 4 Azacitidine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02298348 2026-03-23

N2013-02

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Active not recruiting

Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡